Y-mAbs Therapeutics, Inc. (YSON) Stock Analysis & DCF Valuation
YSON · NASDAQ ·
Medium confidence
Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on developing antibody-based cancer treatments. Sentiment remains cautious.
Y-mAbs Therapeutics, Inc. Intrinsic Value & DCF Valuation
Our discounted cash flow (DCF) model estimates Y-mAbs Therapeutics, Inc. fair value at $NaN per share, compared to the current market price of $NaN. This implies -39.2% downside from today's price.
| Fair Value (DCF) | $NaN |
| Current Market Price | $NaN |
| Upside / Downside | -39.2% |
YSON Key Financial Metrics
| Market Cap | $442.15M |
| P/E Ratio | N/A |
| Dividend Yield | 0.00% |
| Analyst Target Price | $10.00 |
Y-mAbs Therapeutics, Inc. Long-Term Stock Outlook
The company's long-term viability depends on expanding the reach of its existing portfolio and successful clinical trial readouts for new pipeline assets.
Bullish Factors
- [object Object]
- [object Object]
- [object Object]
Key Risks
- [object Object]
- [object Object]
- [object Object]
YSON Analyst Sentiment & Market Consensus
Market sentiment is currently neutral as investors weigh commercial progress against persistent financial hurdles in a volatile biotech sector.
Should You Buy YSON Stock?
Recommendation: Sell Medium confidence
No recommendation provided
Frequently Asked Questions
Is YSON a good stock to buy?
Based on our AI analysis, Y-mAbs Therapeutics, Inc. (YSON) is rated as Sell with medium confidence. Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on developing antibody-based cancer treatments. Sentiment remains cautious.
What is YSON stock price target?
Our DCF valuation model estimates Y-mAbs Therapeutics, Inc. (YSON) fair value at $NaN, suggesting -39.2% downside potential from current price of $NaN.
What is YSON fair value?
The fair value for Y-mAbs Therapeutics, Inc. (YSON) is estimated at $NaN based on discounted cash flow (DCF) analysis. This represents -39.2% downside from the current price.
*This analysis is for informational purposes only and should not be taken as financial advice.*
© 2025 stockpickr - AI-Powered Stock Analysis